[Company analysis] Sumitomo Dainippon Pharma Co., Ltd. (大日本住友製薬)

「Sumitomo Dainippon Pharma Co., Ltd. (大日本住友製薬)」is a subsidiary to the「Sumitomo Chemical Co., Ltd.(住友化学)」and headquartered in Osaka. Basically, their main business is ethical drugs, and they also conduct food material chemicals and veterinary drugs. As a Japanese pharmaceutical company, it has the eighth largest sales volume. The number of consolidated employees is about 6,177.

 

1. Company Profile

2. Summary and Features

3. Major Business

4. Financial Information

 

 

 

1. Company Profile

 

※Unit is JPY million, as of 2019

Company name	Sumitomo Dainippon Pharma Co., Ltd.
Company name (Japanese)	大日本住友製薬
Date of establishment	May 14, 1897
Headquarters location	大阪市中央区道修町 2-6-8
Capital	22,400
Consolidated sales	459,267
Consolidated operating profit	57,884
Consolidated total assets	834,717
Consolidated capital	498,138
Capital adequacy ratio	59.7%
Consolidated number of employees	6,177

 

 

 

2. Summary and Features

 
「Dainippon Sumitomo Pharma」started operations with equipment imported from Germany in 1885 and merged 「Osaka Pharma(大阪製薬)」in 1898. And 2005, the merger of「Sumitomo Pharmaceuticals(住友製薬)」 led them have a wide range of over-the-counter drugs.

Their pharmaceutical business focuses on three main areas: neuropsychiatric, diabetes and specialty. In the psychiatric area, they have therapeutics for Parkinson's disease and schizophrenia, and in the area of ​​diabetes, they have a variety of therapeutic agents for the mechanism of action. 「Sumitomo Pharmaceuticals」also specialize in rare diseases, blood, and cancer in specialty fields that require a high degree of expertise.

However, compare with other pharmaceutical companies, 「Sumitomo Pharmaceuticals」is weak in product appeal, oversea business and R&D. To overcome this, they purchased「Boston Biomedical」in 2012, and taking the anti-cancer agent business as a new source of growth. Besides, this company focused to expand sales of Latuda, a psychotropic drug for the treatment of schizophrenia and other diseases, in North America. And they succeed in increasing it by nearly 50% in 2018.

 

 

3. Major Business

 

■ Pharmaceutical business

■ Food materials and chemical products business

■ Animal Health Business

 

 

 

4. Financial information

 

※Unit is JPY million

		2016	2017	2018
Consolidated sales		408,357	466,838	459,267
Consolidated operating profit		40,286	88,173	57,884
Consolidated total assets		779,072	809,684	834,717
Consolidated net assets		412,268	452,723	498,138
Breakdown of sales	Japan	140,849	143,325	129,287
	North America	194,652	240,791	252,542
	China	17,625	23,444	24,749
	Oversea others	11,543	16,468	14,287
	Others	43,688	42,810	38,402